DEXIUM/LABS

Dexium Labs / iOS

ComicScout iOS

Identify the exact comic edition before pricing.

Live · Publicly available · verified 2026-09-30

Open ComicScout iOS
A translucent blue magnifier character and a green fuzzy companion inspect a stapled comic booklet.

Case 01 / Live iOS

The edition changes the price.

ComicScout is comic identification and market research for the moment when a familiar cover is not enough.

Open ComicScout iOS →
01 / Input

A cover, barcode, or issue detail.

02 / Identity

Series, issue, year, and edition are resolved.

03 / Drift

Variant conflict stays visible instead of being averaged away.

04 / Market

Available sold-market signals are interpreted with their limits.

05 / Action

The collector decides what to inspect next.

Identity is not decoration.

The product decision starts with the specific comic, not a generic image match.

Sold comps are a bounded signal.

Completeness varies. Asking prices and incomplete comparables must not masquerade as a final valuation.

Refusal is useful.

When edition evidence conflicts, the safe result is another inspection—not invented certainty.

Public proof has a date.

The verified record supports the public App Store destination, not every possible workflow outcome.

Decision supported · Snap

ComicScout’s official App Store listing was visible during the recorded refresh.

Inspect source

Destination refreshcomicscout-ios-destination-refresh

Method
Fresh browser inspection of the official Apple App Store listing, HTTPS response check, and DNS A and AAAA resolution with dig
Verified
Scope
Recorded public destination refresh.
Result
success
Limitation
This refresh records the visible public workflow only; it does not establish claims beyond the observed gate.

Verified public destination

Public iOS listing observed on 2026-09-30. The registry records destination availability separately from sold-comp completeness.

Outcome and evolution

Verified learning: product identity must precede market interpretation. Next proof: publish workflow evidence without overstating valuation coverage.